Table II.
Family member | Gender | Age (years) | p.Asp496* mutation | PS activity (%) | Total PS antigen (%) | Free PS antigen (%) | Clinical manifestation |
---|---|---|---|---|---|---|---|
I- 1 | M | 82 | ND | ND | ND | ND | Negative |
I- 2 | F | 79 | ND | ND | ND | ND | Negative |
II- 3 | F | 52 | Positive | 41 | 58 | 52 | Large area cerebral infarct |
II- 4 | M | 50 | Positive | 37 | 46 | 50 | Large area cerebral infarct |
III- 5 | M | 25 | Positive | 32 | 50 | 35 | Negative |
III- 6 | F | 22 | Negative | 88 | 114 | 97 | Negative |
III- 7 | F | 26 | Negative | 85 | 80 | 123 | Negative |
III- 8 | F | 24 | Positive | 39 | 40 | 43 | Negative |
III- 9 | M | 21 | Negative | 80 | 73 | 83 | Negative |
Reference range: PS activity, 65–130%;total PS antigen, 70–130%; free PS antigen, 65–130%. M, male; F, female; ND, not determined.